Antonia P. M.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Healthcare and Patient Time Efficiency in Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab for HER2-Positive Early Breast Cancer
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- Comparative Evaluation of Giredestrant and Triptorelin Versus Anastrozole and Triptorelin in Premenopausal ER-Positive/HER2-Negative Early Breast Cancer
Data & Insights
Has run more than one trial at 324 of 592 partner sites.
Specializations
HER2-Positive Breast Cancer
The investigator specializes in treating HER2-positive breast cancer through various therapeutic approaches, including novel targeted therapies and innovative treatment combinations.
- Trastuzumab-based therapies
- Trastuzumab Deruxtecan applications
- Early-stage disease management
Particular focus on treating residual disease and developing strategies for high-risk patients following neoadjuvant therapy.
Triple-Negative Breast Cancer
Expertise in treating triple-negative breast cancer with emphasis on immunotherapy approaches and precision medicine strategies.
- Immunotherapy combinations
- Early-stage TNBC treatment
- Tumor-infiltrating lymphocyte assessment
Focus on developing personalized treatment approaches based on biological markers and patient characteristics.
Hormone Receptor-Positive Disease
Specialized in treating hormone receptor-positive breast cancer with advanced endocrine therapies and targeted treatment combinations.
- Endocrine therapy optimization
- CDK4/6 inhibitor treatments
- Novel therapeutic combinations
Emphasis on addressing treatment resistance and developing new therapeutic strategies for advanced disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.